Skip to main content

Advertisement

Table 2 Medication in the study groups at baseline

From: Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia

  Diet (n = 14) Diet-plus-statin (n = 14) P value
Antihypertensive agents (n (%))    
 Angiotensin II receptor blockers 12 (86) 10 (71) 0.324
 Angiotensin-converting enzyme inhibitors 2 (14) 0 (0) 0.241
 Calcium-channel blockers 10 (71) 8 (57) 0.430
 Diuretics 4 (29) 3 (21) 0.500
 β-blockers 4 (29) 3 (21) 0.500
 α-blockers 1 (7) 0 (0) 0.500
 Central sympatholytic agents 0 (0) 1 (7) 0.500
Glucose-lowering agents (n (%))    
 Insulin and insulin analougues 0 (0) 0 (0) -
 Sulfonylureas 0 (0) 2 (14) 0.241
 α-glucosidase inhibitors 3 (21) 1 (7) 0.298
 Biguanides 1 (7) 0 (0) 0.500
 Thiazolidinediones 0 (0) 1 (7) 0.500
Lipid-lowering agents (n (%)) 0 (0) 0 (0) -
Antiplatelet agents (n (%)) 2 (14) 3 (21) 0.500
  1. Values are number (percentage)